Bank of Cyprus Oncology Centre Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2016
NCT02705820
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Bank of Cyprus Oncology Center BOCOC

Active Ingredients

Drugs in Phase 2 Trials (1)

pembrolizumab (keytruda) (1 trial)

Drugs in Other Trials (2)

honey (1 trial)

thyme (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3